WhiteOak Capital Pharma and Healthcare Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹304 Cr
Expense Ratio
0.55%
ISIN
INF03VN01886
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
About this fund
As of 17-Apr-25, it has a Net Asset Value (NAV) of ₹12.97, Assets Under Management (AUM) of 303.62 Crores, and an expense ratio of 0.55%.
- WhiteOak Capital Pharma and Healthcare Fund Direct Growth has given a CAGR return of 24.34% since inception.
- The fund's asset allocation comprises around 92.88% in equities, 0.00% in debts, and 7.12% in cash & cash equivalents.
- You can start investing in WhiteOak Capital Pharma and Healthcare Fund Direct Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+29.03%
+17.55% (Cat Avg.)
Since Inception
+24.34%
— (Cat Avg.)
Portfolio Summaryas of 31st March 2025
| Equity | ₹282.02 Cr | 92.88% |
| Others | ₹21.6 Cr | 7.12% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹34.3 Cr | 11.30% |
| Cipla Ltd | Equity | ₹22.44 Cr | 7.39% |
| Divi's Laboratories Ltd | Equity | ₹18.47 Cr | 6.08% |
| Lupin Ltd | Equity | ₹16.93 Cr | 5.58% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹15.6 Cr | 5.14% |
| Torrent Pharmaceuticals Ltd | Equity | ₹11.89 Cr | 3.91% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹11.68 Cr | 3.85% |
| Fortis Healthcare Ltd | Equity | ₹11.57 Cr | 3.81% |
| Laurus Labs Ltd | Equity | ₹10.76 Cr | 3.54% |
| Piramal Pharma Ltd | Equity | ₹8.26 Cr | 2.72% |
| Net Receivables / (Payables) | Cash | ₹8.01 Cr | 2.64% |
| Ipca Laboratories Ltd | Equity | ₹7.8 Cr | 2.57% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹7.48 Cr | 2.46% |
| Ajanta Pharma Ltd | Equity | ₹6.5 Cr | 2.14% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹6.14 Cr | 2.02% |
| Abbott India Ltd | Equity | ₹5.97 Cr | 1.97% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹5.94 Cr | 1.96% |
| Biocon Ltd | Equity | ₹5.54 Cr | 1.82% |
| Poly Medicure Ltd | Equity | ₹5.08 Cr | 1.67% |
| Neuland Laboratories Limited | Equity | ₹4.46 Cr | 1.47% |
| Global Health Ltd | Equity | ₹4.32 Cr | 1.42% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹4.2 Cr | 1.38% |
| Rainbow Childrens Medicare Ltd | Equity | ₹4.08 Cr | 1.34% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹3.95 Cr | 1.30% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹3.89 Cr | 1.28% |
| Supriya Lifescience Ltd | Equity | ₹3.84 Cr | 1.27% |
| Alembic Pharmaceuticals Ltd | Equity | ₹3.61 Cr | 1.19% |
| Ami Organics Ltd | Equity | ₹3.5 Cr | 1.15% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹3.48 Cr | 1.15% |
| Mankind Pharma Ltd | Equity | ₹3.4 Cr | 1.12% |
| Strides Pharma Science Ltd | Equity | ₹3.3 Cr | 1.09% |
| AstraZeneca Pharma India Ltd | Equity | ₹3.07 Cr | 1.01% |
| 91 Days Tbill Red 08-05-2025 | Bond - Gov't/Treasury | ₹2.98 Cr | 0.98% |
| Thyrocare Technologies Ltd | Equity | ₹2.94 Cr | 0.97% |
| Shaily Engineering Plastics Ltd | Equity | ₹2.72 Cr | 0.90% |
| Sai Life Sciences Ltd | Equity | ₹2.62 Cr | 0.86% |
| Laxmi Dental Ltd | Equity | ₹2.6 Cr | 0.86% |
| RPG Life Sciences Ltd | Equity | ₹2.56 Cr | 0.84% |
| Navin Fluorine International Ltd | Equity | ₹2.39 Cr | 0.79% |
| Blue Jet Healthcare Ltd | Equity | ₹2.3 Cr | 0.76% |
| 364 DTB 23052025 | Bond - Gov't/Treasury | ₹1.98 Cr | 0.65% |
| Emcure Pharmaceuticals Ltd | Equity | ₹1.81 Cr | 0.60% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹1.71 Cr | 0.56% |
| PB Fintech Ltd | Equity | ₹1.66 Cr | 0.55% |
| Jubilant Ingrevia Ltd Ordinary Shares | Equity | ₹1.38 Cr | 0.45% |
| Alkyl Amines Chemicals Ltd | Equity | ₹1.15 Cr | 0.38% |
| 91 DTB 10042025 | Bond - Gov't/Treasury | ₹1 Cr | 0.33% |
| 91 DTB 17042025 | Bond - Gov't/Treasury | ₹1 Cr | 0.33% |
| Zota Health Care Ltd | Equity | ₹0.7 Cr | 0.23% |
| 91 Days Tbill Red 24-04-2025 | Bond - Gov't/Treasury | ₹0.5 Cr | 0.16% |
| 182 DTB 05062025 | Bond - Gov't/Treasury | ₹0.2 Cr | 0.07% |
Allocation By Market Cap (Equity)
Large Cap Stocks
28.69%
Mid Cap Stocks
27.15%
Small Cap Stocks
34.72%
Allocation By Credit Quality (Debt)
AAA
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹264.77 Cr | 87.20% |
| Basic Materials | ₹11.13 Cr | 3.67% |
| Financial Services | ₹1.66 Cr | 0.55% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Fund Managers
Piyush Baranwal
Since February 2024
Ramesh Mantri
Since February 2024
Dheeresh Pathak
Since February 2024
Ashish Agrawal
Since January 2025
Additional Scheme Detailsas of 31st March 2025
ISIN INF03VN01886 | Expense Ratio 0.55% | Exit Load 1.00% | Fund Size ₹304 Cr | Age 1 year 2 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
| Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
| PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
| PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
| WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
| WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
| DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
| Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
| Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
| HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Risk Level
Your principal amount will be at Very High Risk
Take control of your wealth
Related Articles
Still got questions?
We're here to help.
What is the current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
What is the portfolio composition of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
Who manages the WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
- Piyush Baranwal
- Ramesh Mantri
- Dheeresh Pathak
- Ashish Agrawal
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹304 Cr
Expense Ratio
0.55%
ISIN
INF03VN01886
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
Risk Level
Your principal amount will be at Very High Risk
About this fund
As of 17-Apr-25, it has a Net Asset Value (NAV) of ₹12.97, Assets Under Management (AUM) of 303.62 Crores, and an expense ratio of 0.55%.
- WhiteOak Capital Pharma and Healthcare Fund Direct Growth has given a CAGR return of 24.34% since inception.
- The fund's asset allocation comprises around 92.88% in equities, 0.00% in debts, and 7.12% in cash & cash equivalents.
- You can start investing in WhiteOak Capital Pharma and Healthcare Fund Direct Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+29.03%
+17.55% (Cat Avg.)
Since Inception
+24.34%
— (Cat Avg.)
Portfolio Summaryas of 31st March 2025
| Equity | ₹282.02 Cr | 92.88% |
| Others | ₹21.6 Cr | 7.12% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹34.3 Cr | 11.30% |
| Cipla Ltd | Equity | ₹22.44 Cr | 7.39% |
| Divi's Laboratories Ltd | Equity | ₹18.47 Cr | 6.08% |
| Lupin Ltd | Equity | ₹16.93 Cr | 5.58% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹15.6 Cr | 5.14% |
| Torrent Pharmaceuticals Ltd | Equity | ₹11.89 Cr | 3.91% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹11.68 Cr | 3.85% |
| Fortis Healthcare Ltd | Equity | ₹11.57 Cr | 3.81% |
| Laurus Labs Ltd | Equity | ₹10.76 Cr | 3.54% |
| Piramal Pharma Ltd | Equity | ₹8.26 Cr | 2.72% |
| Net Receivables / (Payables) | Cash | ₹8.01 Cr | 2.64% |
| Ipca Laboratories Ltd | Equity | ₹7.8 Cr | 2.57% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹7.48 Cr | 2.46% |
| Ajanta Pharma Ltd | Equity | ₹6.5 Cr | 2.14% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹6.14 Cr | 2.02% |
| Abbott India Ltd | Equity | ₹5.97 Cr | 1.97% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹5.94 Cr | 1.96% |
| Biocon Ltd | Equity | ₹5.54 Cr | 1.82% |
| Poly Medicure Ltd | Equity | ₹5.08 Cr | 1.67% |
| Neuland Laboratories Limited | Equity | ₹4.46 Cr | 1.47% |
| Global Health Ltd | Equity | ₹4.32 Cr | 1.42% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹4.2 Cr | 1.38% |
| Rainbow Childrens Medicare Ltd | Equity | ₹4.08 Cr | 1.34% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹3.95 Cr | 1.30% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹3.89 Cr | 1.28% |
| Supriya Lifescience Ltd | Equity | ₹3.84 Cr | 1.27% |
| Alembic Pharmaceuticals Ltd | Equity | ₹3.61 Cr | 1.19% |
| Ami Organics Ltd | Equity | ₹3.5 Cr | 1.15% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹3.48 Cr | 1.15% |
| Mankind Pharma Ltd | Equity | ₹3.4 Cr | 1.12% |
| Strides Pharma Science Ltd | Equity | ₹3.3 Cr | 1.09% |
| AstraZeneca Pharma India Ltd | Equity | ₹3.07 Cr | 1.01% |
| 91 Days Tbill Red 08-05-2025 | Bond - Gov't/Treasury | ₹2.98 Cr | 0.98% |
| Thyrocare Technologies Ltd | Equity | ₹2.94 Cr | 0.97% |
| Shaily Engineering Plastics Ltd | Equity | ₹2.72 Cr | 0.90% |
| Sai Life Sciences Ltd | Equity | ₹2.62 Cr | 0.86% |
| Laxmi Dental Ltd | Equity | ₹2.6 Cr | 0.86% |
| RPG Life Sciences Ltd | Equity | ₹2.56 Cr | 0.84% |
| Navin Fluorine International Ltd | Equity | ₹2.39 Cr | 0.79% |
| Blue Jet Healthcare Ltd | Equity | ₹2.3 Cr | 0.76% |
| 364 DTB 23052025 | Bond - Gov't/Treasury | ₹1.98 Cr | 0.65% |
| Emcure Pharmaceuticals Ltd | Equity | ₹1.81 Cr | 0.60% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹1.71 Cr | 0.56% |
| PB Fintech Ltd | Equity | ₹1.66 Cr | 0.55% |
| Jubilant Ingrevia Ltd Ordinary Shares | Equity | ₹1.38 Cr | 0.45% |
| Alkyl Amines Chemicals Ltd | Equity | ₹1.15 Cr | 0.38% |
| 91 DTB 10042025 | Bond - Gov't/Treasury | ₹1 Cr | 0.33% |
| 91 DTB 17042025 | Bond - Gov't/Treasury | ₹1 Cr | 0.33% |
| Zota Health Care Ltd | Equity | ₹0.7 Cr | 0.23% |
| 91 Days Tbill Red 24-04-2025 | Bond - Gov't/Treasury | ₹0.5 Cr | 0.16% |
| 182 DTB 05062025 | Bond - Gov't/Treasury | ₹0.2 Cr | 0.07% |
Allocation By Market Cap (Equity)
Large Cap Stocks
28.69%
Mid Cap Stocks
27.15%
Small Cap Stocks
34.72%
Allocation By Credit Quality (Debt)
AAA
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹264.77 Cr | 87.20% |
| Basic Materials | ₹11.13 Cr | 3.67% |
| Financial Services | ₹1.66 Cr | 0.55% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Fund Managers
Piyush Baranwal
Since February 2024
Ramesh Mantri
Since February 2024
Dheeresh Pathak
Since February 2024
Ashish Agrawal
Since January 2025
Additional Scheme Detailsas of 31st March 2025
ISIN INF03VN01886 | Expense Ratio 0.55% | Exit Load 1.00% | Fund Size ₹304 Cr | Age 1 year 2 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
|---|---|---|---|---|
| Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
| Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
| PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
| PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
| WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
| WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
| DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
| Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
| Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
| HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Related Articles
Still got questions?
We're here to help.
What is the current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
What is the portfolio composition of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
Who manages the WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
- Piyush Baranwal
- Ramesh Mantri
- Dheeresh Pathak
- Ashish Agrawal
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
Track all you investments in one place
Download Wealth Monitor App
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Get your portfolio reviewed by experts
